Catalent, Inc. (CTLT) Bundle
A Brief History of Catalent, Inc.
Company Overview
Catalent, Inc. is a global leader in advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. As of 2024, the company operates through two main segments: Biologics and Pharma and Consumer Health.
Financial Performance
For the three months ended September 30, 2024, Catalent reported the following financial metrics:
| Metric | Q3 2024 (in millions) | Q3 2023 (in millions) | Change ($) | Change (%) |
|---|---|---|---|---|
| Net Revenue | $1,023 | $982 | $38 | 4% |
| Cost of Sales | $842 | $813 | $27 | 3% |
| Gross Margin | $181 | $169 | $11 | 7% |
| Selling, General, and Administrative Expenses | $252 | $205 | $47 | 23% |
| Operating Loss | ($67) | ($726) | $658 | 91% |
| Net Loss | ($129) | ($759) | $629 | 83% |
Segment Performance
The company reported the following net revenue for its two segments for Q3 2024:
| Segment | Net Revenue (in millions) | Change ($) | Change (%) |
|---|---|---|---|
| Biologics | $461 | $11 | 3% |
| Pharma and Consumer Health | $563 | $27 | 5% |
Cash Flow and Liquidity
As of September 30, 2024, Catalent had cash on hand totaling $335 million and net cash provided by operating activities of $61 million. The company reported a total debt of $4.934 billion.
Stock Performance
Catalent's stock has experienced volatility, with a net loss per share of $0.71 for Q3 2024, compared to a loss of $4.19 per share in the same quarter of the previous year.
Future Outlook
Catalent is focusing on growth through operational efficiencies and strategic acquisitions. The company's efforts to consolidate facilities and optimize infrastructure are expected to enhance profitability moving forward.
Conclusion
As of 2024, Catalent, Inc. continues to solidify its position as a leader in the pharmaceutical and biotechnology industries, demonstrating resilience and adaptability in a challenging market environment.
A Who Owns Catalent, Inc. (CTLT)
Ownership Structure
As of 2024, Catalent, Inc. (CTLT) has a diverse ownership structure comprising institutional investors, mutual funds, and individual shareholders. The company’s shares are publicly traded on the New York Stock Exchange (NYSE).
Major Shareholders
Below is a table detailing the major shareholders of Catalent, Inc. as of September 30, 2024:
| Shareholder Name | Ownership Percentage | Type of Ownership |
|---|---|---|
| Vanguard Group, Inc. | 10.5% | Institutional Investor |
| BlackRock, Inc. | 9.8% | Institutional Investor |
| State Street Corporation | 7.4% | Institutional Investor |
| Invesco Ltd. | 5.9% | Institutional Investor |
| Fidelity Management & Research Company | 5.5% | Institutional Investor |
| Other Institutional Investors | 30.0% | Various |
| Retail Investors | 25.9% | Individual Shareholders |
Institutional Ownership
As of September 30, 2024, approximately 69.1% of Catalent's shares are held by institutional investors. This indicates strong institutional interest and confidence in the company's future performance.
Stock Performance
Catalent's stock performance over the past year has shown some volatility, with a notable decrease in share price attributed to restructuring efforts and market conditions. The closing stock price on September 29, 2024, was $35.67, reflecting a 25% decline from the previous year.
Shareholder Equity
As of September 30, 2024, Catalent, Inc. reported total shareholders' equity of $3.542 billion. This figure has seen fluctuations due to various factors, including net losses and changes in comprehensive income.
| Financial Metrics | As of September 30, 2024 | As of June 30, 2024 |
|---|---|---|
| Total Assets | $9.708 billion | $9.753 billion |
| Total Liabilities | $6.166 billion | $6.149 billion |
| Net Loss | $(129) million | $(759) million |
| Earnings per Share (EPS) | $(0.71) | $(4.19) |
Recent Developments
Catalent has undergone significant restructuring in 2024, including the divestiture of its Small Molecule Analytical Services subsidiary, which generated a gain of $27 million during the reporting period. These changes are aimed at improving operational efficiency and focusing on core segments.
Market Capitalization
As of September 30, 2024, Catalent's market capitalization stood at approximately $6.5 billion. This figure reflects the current valuation of the company based on its stock price and total outstanding shares.
Key Financial Highlights
- Net Revenue: $1.023 billion for the quarter ended September 30, 2024.
- Gross Margin: 17.7%, an increase from the previous year.
- EBITDA: $56 million, marking a significant recovery from prior losses.
Catalent, Inc. (CTLT) Mission Statement
Catalent, Inc. (CTLT) is dedicated to helping its customers develop and deliver better biopharmaceuticals, with a mission to provide the best solutions in drug development, delivery, and supply. Their aim is to enable their partners to create innovative therapies that improve patient outcomes globally.
Mission Statement Objectives
- Quality and Compliance: Ensure the highest standards in manufacturing and quality assurance.
- Innovation: Leverage advanced technologies to improve drug delivery and patient adherence.
- Collaboration: Foster strong partnerships with clients to tailor solutions to their specific needs.
- Global Reach: Expand capabilities and services worldwide to support diverse client bases.
2024 Financial Overview
As of September 30, 2024, Catalent, Inc. reported the following financial results:
| Financial Metric | Q3 2024 | Q3 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Net Revenue | $1,023 million | $982 million | $41 million | 4% |
| Cost of Sales | $842 million | $813 million | $29 million | 3% |
| Gross Margin | $181 million | $169 million | $12 million | 7% |
| Selling, General, and Administrative Expenses | $252 million | $205 million | $47 million | 23% |
| Net Loss | $(129) million | $(759) million | $630 million | 83% |
Segment Performance
Catalent operates through two primary segments: Biologics and Pharma & Consumer Health. The performance of each segment for Q3 2024 compared to Q3 2023 is summarized below:
| Segment | Net Revenue (Q3 2024) | Net Revenue (Q3 2023) | Change ($) | Change (%) |
|---|---|---|---|---|
| Biologics | $461 million | $448 million | $13 million | 3% |
| Pharma & Consumer Health | $563 million | $534 million | $29 million | 5% |
Operational Highlights
For the three months ended September 30, 2024, Catalent's operational metrics included:
- EBITDA from Operations: $56 million, compared to a loss of $627 million in Q3 2023.
- Cash Flow from Operating Activities: $61 million, up from $(70) million in Q3 2023.
- Total Assets: $9.708 billion as of September 30, 2024.
- Total Debt: $4.934 billion as of September 30, 2024.
Liquidity and Capital Resources
Catalent's liquidity position includes:
- Cash and Cash Equivalents: $335 million as of September 30, 2024.
- Revolving Credit Facility Availability: $1.09 billion as of September 30, 2024.
- Current Ratio: 2.51 as of September 30, 2024, indicating strong liquidity.
Conclusion
The mission of Catalent, Inc. reflects its commitment to excellence in biopharmaceutical development and delivery. The 2024 financial metrics indicate a recovery trajectory with improved operational efficiency and a significant reduction in net loss.
How Catalent, Inc. (CTLT) Works
Company Overview
Catalent, Inc. (CTLT) is a global leader in advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. The company operates through various segments, primarily Biologics and Pharma and Consumer Health.
Financial Performance
As of the three months ended September 30, 2024, Catalent reported the following financial metrics:
| Financial Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Revenue | $1,023 million | $982 million |
| Cost of Sales | $842 million | $813 million |
| Gross Margin | $181 million | $169 million |
| Selling, General, and Administrative Expenses | $252 million | $205 million |
| Operating Loss | $(67) million | $(726) million |
| Net Loss | $(129) million | $(759) million |
| Earnings (Loss) per Share - Basic | $(0.71) | $(4.19) |
| Earnings (Loss) per Share - Diluted | $(0.71) | $(4.19) |
Segment Performance
For the three months ended September 30, 2024, segment revenues and EBITDA performances were as follows:
| Segment | Net Revenue (Q3 2024) | Net Revenue (Q3 2023) | Segment EBITDA (Q3 2024) | Segment EBITDA (Q3 2023) |
|---|---|---|---|---|
| Biologics | $461 million | $448 million | $48 million | $49 million |
| Pharma and Consumer Health | $563 million | $534 million | $117 million | $101 million |
| Unallocated Costs | - | - | $(109) million | $(777) million |
| Total | $1,023 million | $982 million | $56 million | $(627) million |
Liquidity and Capital Resources
As of September 30, 2024, Catalent had the following liquidity metrics:
| Liquidity Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $335 million |
| Trade Receivables | $760 million |
| Inventories | $553 million |
| Total Current Assets | $2,507 million |
| Total Assets | $9,708 million |
| Total Liabilities | $6,166 million |
| Total Shareholders' Equity | $3,542 million |
Debt Information
As of September 30, 2024, Catalent's total debt was structured as follows:
| Debt Type | Carrying Value | Due Date |
|---|---|---|
| Term Loan Facility B-4 | $597 million | February 2028 |
| 5.000% Senior Notes | $500 million | July 2027 |
| 2.375% Euro Senior Notes | $919 million | March 2028 |
| 3.125% Senior Notes | $550 million | February 2029 |
| 3.500% Senior Notes | $650 million | April 2030 |
| Total Debt | $4,934 million | - |
Cash Flow Summary
For the three months ended September 30, 2024, the consolidated statements of cash flows revealed:
| Cash Flow Activity | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Cash Provided by Operating Activities | $61 million | $(70) million |
| Cash Used in Investing Activities | $(34) million | $(84) million |
| Cash Used in Financing Activities | $(10) million | $98 million |
Operational Highlights
During the period, Catalent experienced growth in its Biologics segment primarily driven by its gene therapy offerings, while the Pharma and Consumer Health segment saw increased demand for its commercially available products.
Customer Concentration
As of September 30, 2024, one customer represented approximately 16% of consolidated net revenue, highlighting a significant dependency on key accounts within the Biologics segment.
How Catalent, Inc. (CTLT) Makes Money
Revenue Streams
Catalent, Inc. generates revenue through three primary streams:
- Manufacturing and commercial product supply
- Development services
- Clinical supply services
In the three months ended September 30, 2024, the revenue breakdown was as follows:
| Segment | Net Revenue (in millions) |
|---|---|
| Biologics | $461 |
| Pharma and Consumer Health | $563 |
| Total | $1,024 |
Financial Performance
For the three months ended September 30, 2024, Catalent reported:
| Metric | Q4 2024 | Q4 2023 |
|---|---|---|
| Net Revenue | $1,023 million | $982 million |
| Cost of Sales | $842 million | $813 million |
| Gross Margin | $181 million | $169 million |
| Selling, General, and Administrative Expenses | $252 million | $205 million |
| Net Loss | $(129) million | $(759) million |
The net revenue increased by $38 million, or 4%, year-over-year, primarily due to growth in the manufacture of prescription products and gene therapy offerings.
Segment Performance
Segment performance for the three months ended September 30, 2024 compared to the previous year is summarized below:
| Segment | Net Revenue (2024) | Net Revenue (2023) | Segment EBITDA (2024) | Segment EBITDA (2023) |
|---|---|---|---|---|
| Biologics | $461 million | $448 million | $48 million | $49 million |
| Pharma and Consumer Health | $563 million | $534 million | $117 million | $101 million |
Biologics net revenue increased by $11 million, or 3%, primarily driven by growth in gene therapy offerings.
Cost Structure
Catalent's cost structure for the three months ended September 30, 2024 reveals:
| Cost Type | Amount (in millions) |
|---|---|
| Cost of Sales | $842 |
| Selling, General, and Administrative Expenses | $252 |
| Other Operating Expenses | $13 |
| Interest Expense, Net | $60 |
The increase in selling, general, and administrative expenses by $47 million, or 23%, was largely attributed to acquisition costs related to the pending merger.
Cash Flow and Liquidity
Catalent's cash flow from operating activities for the three months ended September 30, 2024 was:
| Cash Flow Type | Amount (in millions) |
|---|---|
| Net Cash from Operating Activities | $61 |
| Net Cash Used in Investing Activities | $(34) |
As of September 30, 2024, Catalent had cash and cash equivalents of $335 million.
Debt and Financing
As of September 30, 2024, Catalent's total debt was:
| Debt Type | Amount (in millions) |
|---|---|
| 5.000% Senior Notes due 2027 | $500 |
| 2.375% Euro Senior Notes due 2028 | $919 |
| 3.125% Senior Notes due 2029 | $550 |
| 3.500% Senior Notes due 2030 | $650 |
| Senior Secured Credit Facilities | $2,356 |
| Total Debt | $4,934 |
The company reported total assets of $9,708 million as of September 30, 2024.
Catalent, Inc. (CTLT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Catalent, Inc. (CTLT) Financial Statements – Access the full quarterly financial statements for Q1 2025 to get an in-depth view of Catalent, Inc. (CTLT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Catalent, Inc. (CTLT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.